Denver, CO // The new partnership will give oncologists who use Perthera access to the world’s only phosphoprotein panel LDT that directly measures the activation state of targets of over 100 precision therapeutics at once. Perthera will serve as Theralink’s CRO to help bring in and enroll oncology practices in Theralink’s TRACE program, as well as provide treatment matching services to Theralink’s oncology partners.
Perthera and Theralink Technologies Announce Partnership to Allow for Unique Access to Phosphoproteomic Profiling and Drug Target Activation Testing
AI-enabled precision, speed and scale
Precision oncology and speed to decision, for everyone, at every point of care.How We Help